格菲妥单抗联合Pola-R-CHP或R-CHOP作为年轻高危大B细胞淋巴瘤患者的一线治疗:COALITION研究结果
COALITION是一项研究者发起的II期试验,纳入≤65岁、至少具有一项高危特征的大B细胞淋巴瘤患者,先接受1周期R-CHOP后随机分配至5周期Glofit-Pola-R-CHP组(n=40)或Glofit-R-CHOP组(n=40),再接受2周期格菲妥单抗巩固治疗。主要终点为安全性与治疗可交付性,次要终点包括缓解率和生存。80例可评估患者中位年龄58岁,总代谢肿瘤体积842 cm3,自诊断起中位14天开始治疗,超过95%患者完成全部治疗,中位相对剂量强度>94%。细胞因子释放综合征发生率21%,均为≤2级且可控。总缓解率和完全缓解率分别为100%和98%。中位随访20.7个月时,估计2年无进展生存率和总生存率分别为86%和92%。结论认为格菲妥单抗联合R-CHOP或Pola-R-CHP可交付,并在该年轻高负荷高危大B细胞淋巴瘤人群中产生高比例持久缓解,支持其作为一线治疗的持续探索。
要点
- ≤65岁高危大B细胞淋巴瘤患者中,格菲妥单抗联合R-CHOP或Pola-R-CHP可交付,>95%完成全部治疗。
- 细胞因子释放综合征发生率21%,均为≤2级且可控。
- 总缓解率100%、完全缓解率98%;中位随访20.7个月,估计2年无进展生存率86%、总生存率92%。
核心结论
- 格菲妥单抗联合R-CHOP或Pola-R-CHP可交付,并在该年轻高负荷高危大B细胞淋巴瘤人群中产生高比例持久缓解,支持其作为一线治疗的持续探索。
研究设计与样本
- 研究者发起的II期COALITION试验,纳入年龄≤65岁、至少具有一项高危特征(IPI≥3、NCCN-IPI≥4或MYC与BCL2和/或BCL6重排)的大B细胞淋巴瘤患者。
- 患者先接受1周期R-CHOP,随后随机分配至5周期Glofit-Pola-R-CHP组(n=40)或Glofit-R-CHOP组(n=40),再接受2周期格菲妥单抗巩固治疗;入组可在1周期R-CHOP之前或之后进行。
- 主要终点为安全性和治疗可交付性,次要终点包括缓解率和生存。
主要发现
- 80例可评估患者中位年龄58岁,总代谢肿瘤体积842 cm3,自诊断起中位14天开始治疗。
- 超过95%患者完成全部治疗,中位相对剂量强度>94%。
- 细胞因子释放综合征发生率21%,均为≤2级且可控。
- 总缓解率和完全缓解率分别为100%和98%。
- 中位随访20.7个月时,估计2年无进展生存率和总生存率分别为86%和92%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Improved outcomes are needed for patients with high-risk (HR) large B-cell lymphoma (LBCL) who have <50% chance of cure with first-line (1L) R-CHOP chemotherapy. Patients with high burden or rapid progression are often excluded from 1L trials due to screening requirements. We report the investigator-initiated, phase II COALITION trial of the CD20xCD3 bispecific antibody glofitamab combined with R-CHOP or Pola-R-CHP in younger patients with HR features, designed to minimize time between diagnosis and treatment. METHODS: Patients age ≤65 years with LBCL and at least one HR feature (international prognostic index [IPI] ≥3, National Comprehensive Cancer Network-IPI ≥4, or rearrangements of MYC and BCL2 and/or BCL6) received one cycle of R-CHOP and were randomly assigned to five cycles of Glofit-Pola-R-CHP (n = 40) or Glofit-R-CHOP (n = 40), and two cycles of glofitamab consolidation. Enrollment occurred before or after a cycle of R-CHOP. The primary objective was safety and treatment deliverability. Secondary end points included response rates and survival. RESULTS: Eighty evaluable patients with a median age of 58 years and total metabolic tumor volume of 842 cm3 were included and began treatment a median of 14 days from diagnosis. Over 95% of patients completed all therapy and the median relative dose intensity was >94%. Cytokine release syndrome was observed in 21% of patients, all ≤grade 2 and manageable. Overall and complete response rates were 100% and 98%, respectively. At 20.7-month median follow-up, the estimated 2-year progression-free survival and overall survival were 86% and 92%, respectively. CONCLUSION: The combination of glofitamab with R-CHOP or Pola-R-CHP is deliverable and results in high rates of durable response in this population of younger patients with high-burden, HR LBCL, supporting its ongoing exploration as a 1L treatment.
引用
- Minson A, Verner E, Giri P, et al. Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study. J Clin Oncol. 2025. PMID: 40532125. doi:10.1200/JCO-25-00481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。